{"groups":[{"description":"SP-02L (darinaparsin for injection): Darinaparsin 300 mg/m2 once daily for 5 consecutive days every 21 days","id":"FG000","title":"SP-02L (Darinaparsin for Injection)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"5"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"4"}],"type":"Death"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"65"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"56"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"9"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"67 patients were enrolled and 65 were treated.","recruitmentDetails":"Patients were recruited in Japan, Korea, Taiwan and Hong Kong during the period from March 25, 2016 to September 17, 2019."}